- Home
- SCOR vs IGC Comparison
SCOR vs IGC Comparison
Compare SCOR & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCOR
- IGC
- Stock Information
- Founded
- SCOR 1999
- IGC 2005
- Country
- SCOR United States
- IGC United States
- Employees
- SCOR N/A
- IGC N/A
- Industry
- SCOR Business Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- SCOR Consumer Discretionary
- IGC Health Care
- Exchange
- SCOR Nasdaq
- IGC Nasdaq
- Market Cap
- SCOR 23.9M
- IGC 20.2M
- IPO Year
- SCOR 2007
- IGC N/A
- Fundamental
- Price
- SCOR $5.84
- IGC $0.38
- Analyst Decision
- SCOR Buy
- IGC Strong Buy
- Analyst Count
- SCOR 2
- IGC 2
- Target Price
- SCOR $10.75
- IGC $3.88
- AVG Volume (30 Days)
- SCOR 22.6K
- IGC 6.7M
- Earning Date
- SCOR 08-05-2025
- IGC 08-07-2025
- Dividend Yield
- SCOR N/A
- IGC N/A
- EPS Growth
- SCOR N/A
- IGC N/A
- EPS
- SCOR N/A
- IGC N/A
- Revenue
- SCOR $354,961,000.00
- IGC $1,271,000.00
- Revenue This Year
- SCOR $3.36
- IGC $15.26
- Revenue Next Year
- SCOR $2.72
- IGC $3.41
- P/E Ratio
- SCOR N/A
- IGC N/A
- Revenue Growth
- SCOR N/A
- IGC N/A
- 52 Week Low
- SCOR $4.39
- IGC $0.25
- 52 Week High
- SCOR $15.31
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- SCOR 66.75
- IGC 65.10
- Support Level
- SCOR $4.39
- IGC $0.30
- Resistance Level
- SCOR $5.34
- IGC $0.46
- Average True Range (ATR)
- SCOR 0.32
- IGC 0.02
- MACD
- SCOR 0.09
- IGC 0.01
- Stochastic Oscillator
- SCOR 99.57
- IGC 48.81
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.